Skip to main content

Show 39 results Show all

Forecasting Guide for New and Underutilized Methods of Family Planning

This guide provides direction to programs that want to forecast for new and underused methods (NUMs) of family planning. It supports program managers and others involved in forecasting as they plan to introduce a contraceptive technology for the first time in a country and/or position an underused method for scale-up.

Institutional author(s): Institute for Reproductive Health at Georgetown University, JSI, Reproductive Health Supplies Coalition (RHSC), Population Services International (PSI)
Publication date: June, 2012

Guide Web page

Key Indicators for Community-based Access to Injectable Contraception Pilot Studies

An indicator is a measure of program performance that is tracked over time. This document presents potential process and outcome indicators organized according to the phase of the community-based access to injectables (CBA2I) pilot along with the related evaluation questions, data sources and measurement tools. The list can be adapted to local contexts and program goals to assess a pilot’s progress toward intended outputs and achievement of goals.

Institutional author(s): FHI 360
Publication date: July, 2011

Nine Steps for Developing a Scaling-Up Strategy

The aim of this 35-page guide is to facilitate systematic planning for scaling up. It is intended for program managers, researchers, and technical support agencies who are seeking to scale-up health service innovations that have been tested in pilot projects or other field tests and proven successful.

Institutional author(s): World Health Organization (WHO)
Publication date: June, 2010

DMPA-SC policy and regulatory advocacy landscape

This policy landscape can be leveraged by applicants interested in applying to the DMPA-SC Regulatory Advocacy Catalytic Opportunity Fund (COF). The landscape was originally developed in 2020 to understand policies and regulations, including over-the-counter regulations, that impact women’s access to DMPA-SC and identify short- and long-term advocacy opportunities. In 2022, it was refreshed to understand policy shifts and additional advocacy opportunities in a subset of 12 of the original 18 countries currently eligible for the Regulatory Advocacy COF. Insights from the policy landscape have informed the design and eligibility criteria of the Regulatory Advocacy COF, proactively identified opportunities, and provided frameworks and guidance for interested applicants.

Institutional author(s): Clinton Health Access Initiative (CHAI)
Publication date: 2022

Report

DMPA-SC overbranding and overpackaging in private and social marketing sectors

The desire for private sector family planning programs to have the ability to overbrand/overpackage the Pfizer Inc. DMPA-SC product, Sayana® Press, has existed since initial product introduction planning discussions among global partners in 2008–2009. The PATH-JSI DMPA-SC Access Collaborative solicited input from the team’s regional technical advisors, country coordinators, and local partners to better understand the status of overbranding, and any related advocacy­­, in the countries where we work.

Institutional author(s): PATH, JSI
Publication date: July, 2022

Introducing new self-care family planning methods: Lessons from DMPA-SC and the Caya diaphragm

This webinar held on February 23, 2022 was hosted by Expanding Effective Contraceptive Options (EECO) led by WCG Cares with PSI and the DMPA-SC Access Collaborative led by PATH in partnership with JSI. The discussion focused on the introduction and scale up of self-care family planning methods in sub-Saharan Africa, highlighting lessons and best practices from DMPA-SC scale-up and Caya® diaphragm pilot introductions in French-speaking West Africa. Presenters from Benin, Niger, and Senegal shared successes and challenges. This webinar was offered in French.

Institutional author(s): PATH, JSI, Population Services International (PSI), Association Béninoise pour le Marketing Social et la Communication pour la Santé, Expanding Effective Contraceptive Options
Publication date: February, 2022

Self-injection in the private sector: Promoting policies for progress

The private sector holds great potential to reduce unmet need for family planning, and many countries are poised to adopt a total market approach for increasing contraceptive access through private pharmacies and drug shops. Policies supporting scale-up of family planning service provision and expanding method options such as DMPA-SC self-injection, must be prioritized in these entities.

The PATH-JSI DMPA-SC Access Collaborative and partners have gained valuable insights with relevance to private sector engagement on self-injection. This webinar held February 15, 2022 highlighted lessons learnt, challenges, recommendations, and considerations for policies supporting private sector engagement in self-injection in different country contexts. Specific topics included:

  • Financing and commodity production ecosystems
  • Procurement and supply chains
  • Service delivery and programming
  • Data reporting and monitoring
  • Advocacy
  • Demand generation

The discussion was moderated by Allen Namagembe, Deputy Project Director, Uganda DMPA-SC Access Collaborative, PATH.

Panelists:

  • Dr. Kayode Afolabi, Director and Head, Reproductive Health Division, Federal Ministry of Health, Nigeria
  • Dr. Daniella Munene, Member, National Executive Committee, Pharmaceutical Society of Kenya
  • Dr. Hortense Randrianaivo, President, Association of Pharmacists of Madagascar
  • Mr. Célestin Compaore, Regional Project Director, DMPA-SC, Jhpiego, Burkina Faso

Institutional author(s): PATH, JSI, Jhpiego, Nigeria Federal Ministry of Health, Pharmaceutical Society of Kenya, Association of Pharmacists of Madagascar
Publication date: February, 2022

Strategic planning guide for creating equitable access to high-quality family planning information and services

This strategic planning guide is intended to guide program managers, planners, and decision-makers through a process to identify inequities in family planning and interventions to reduce them. The guide was developed through consultation and deliberation with technical experts in family planning and health equity and builds upon a discussion paper on equity in family planning developed under the Partnership for High Impact Practices for Family Planning.

Institutional author(s): High Impact Practices in Family Planning (HIPs)
Publication date: August, 2021

The Highs, Lows, and Squishy Middle of Contraceptive Product Introduction

As part of the Global Health Science and Practice (GHTechX) conference, CHAI, FHI 360, PATH, the Population Council, PSI, and WCG hosted an April 22, 2021 session to synthesize lessons learned across contraceptive introduction of implants, DMPA-SC self-injection, hormonal IUS and other methods. During the session, experts from Kenya, Madagascar, Uganda, and the United States outlined essential steps for the process of contraceptive product introduction, described common challenges, and shared tools and approaches based on experiences with the three methods. Session slides are available below. To watch the recording of this and many other sessions, register for free on the GHTechX website.

Institutional author(s): Clinton Health Access Initiative (CHAI), FHI 360, PATH, Population Council
Publication date: April, 2021

Evidence to Action (E2A) Expanding Contraceptive Choice resources and tools

This web page features publications from Evidence to Action’s work to expand contraceptive method choice by strengthening services in facilities, advancing community-based family planning, and creating models for effective integration.

Institutional author(s): Evidence to Action (E2A)
Publication date: December, 2020

Tool Web page